Bicara Therapeutics Talks Ficerasfusp Alfa Data, Pivotal Trial Timeline and $172M Raise at Conference

Bicara Therapeutics (NASDAQ:BCAX) is developing tumor-targeting bifunctional antibodies, with its lead candidate ficerasfusp ...